Abstract
Hypercalcemia is a relatively frequent alteration, mostly associated to primary hyperparathyroidism (PHPT) and malignancy-associated hypercalcemia (MAH). Treatment first includes rehydration and loop diuretics, as general measures. Bisphosphonates are considered the drugs of choice due to their long-term management. Calcitonin is preferable in the short-term control of severe hypercalcemia. The antireabsorptive action of bisphosphonates has been considered the most effective in the disorders characterized by an excessive bone resorption. Zoledronate is superior to both clodronate or pamidronate in the treatment of MAH. Calcimimetic agents has been recently introduced to control hypercalcemia in selected cases of PHPT. They are used when surgery is not possible or patients do not meet surgical criteria. Malignancy- associate hypercalcemia is broadly divided into two categories: humoral MAH and osteolytic MAH. The first concerns the paraneoplastic release of humoral factors, mainly parathyroid hormone-related peptide (PTHrP). Recently a humanized monoclonal antibody against human PTHrP has been generated and is still under evaluation. The receptor activator of nuclear factor-κ ligand (RANKL) has a critical role in the etiology of malignancy skeletal complications. The fully humanized anti-RANKL antibody (denosumab) would seem to be even more effective than bisphosphonates to suppress bone resorption, as shown in preliminary results .
Keywords: Hypercalcemia, hyperparathyroidism, bisphosphonates, RANKL, PTHrP, parathyroidectomy, Zoledronate, denosumab, loop diuretics, concomitant natriuretic
Medicinal Chemistry
Title:Treatment of Chronic Hypercalcemia
Volume: 8 Issue: 4
Author(s): Valentina Camozzi, Giovanni Luisetto, Stefano M.M. Basso, Piero Cappelletti, Renato Tozzoli and Franco Lumachi
Affiliation:
Keywords: Hypercalcemia, hyperparathyroidism, bisphosphonates, RANKL, PTHrP, parathyroidectomy, Zoledronate, denosumab, loop diuretics, concomitant natriuretic
Abstract: Hypercalcemia is a relatively frequent alteration, mostly associated to primary hyperparathyroidism (PHPT) and malignancy-associated hypercalcemia (MAH). Treatment first includes rehydration and loop diuretics, as general measures. Bisphosphonates are considered the drugs of choice due to their long-term management. Calcitonin is preferable in the short-term control of severe hypercalcemia. The antireabsorptive action of bisphosphonates has been considered the most effective in the disorders characterized by an excessive bone resorption. Zoledronate is superior to both clodronate or pamidronate in the treatment of MAH. Calcimimetic agents has been recently introduced to control hypercalcemia in selected cases of PHPT. They are used when surgery is not possible or patients do not meet surgical criteria. Malignancy- associate hypercalcemia is broadly divided into two categories: humoral MAH and osteolytic MAH. The first concerns the paraneoplastic release of humoral factors, mainly parathyroid hormone-related peptide (PTHrP). Recently a humanized monoclonal antibody against human PTHrP has been generated and is still under evaluation. The receptor activator of nuclear factor-κ ligand (RANKL) has a critical role in the etiology of malignancy skeletal complications. The fully humanized anti-RANKL antibody (denosumab) would seem to be even more effective than bisphosphonates to suppress bone resorption, as shown in preliminary results .
Export Options
About this article
Cite this article as:
Camozzi Valentina, Luisetto Giovanni, M.M. Basso Stefano, Cappelletti Piero, Tozzoli Renato and Lumachi Franco, Treatment of Chronic Hypercalcemia, Medicinal Chemistry 2012; 8 (4) . https://dx.doi.org/10.2174/157340612801216355
DOI https://dx.doi.org/10.2174/157340612801216355 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vitamin D3 and Vitamin D3 Analogues as an Adjunct to Cancer Chemotherapy and Radiotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Cellular Responses to 24R,25-dihydroxyvitamin D3 in Bone and Cartilage
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Sweet on Hedgehogs: Regulatory Roles of Heparan Sulfate Proteoglycans in Hedgehog-Dependent Cell Proliferation and Differentiation
Current Protein & Peptide Science Control of Inflammatory Bowel Disease and Colorectal Cancer by Synthetic Vitamin D Receptor Ligands
Current Medicinal Chemistry Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer
Current Cancer Drug Targets Pediatric CKD and Cardivascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Systemic Approach to the Study of Complex Bone Disorders at the Whole- Genome Level
Current Genomics Quantitative Proteomics with Isotope Dilution Analysis: Principles and Applications
Current Proteomics Cartilage and Bone Extracellular Matrix
Current Pharmaceutical Design Immune-Neuroendocrine Interactions Involving Thymus and Pineal Gland in Stem Cell Therapy of Age-Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Exploration of the Medicinal Peptide Space
Protein & Peptide Letters Delivery Systems for Biopharmaceuticals. Part I: Nanoparticles and Microparticles
Current Pharmaceutical Biotechnology Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Strategies for Novel Therapeutic Approaches Targeting Cytokines and Signaling Pathways of Osteoclasto- and Osteoblastogenesis in the Fight Against Immune-Mediated Bone and Joint Diseases
Current Medicinal Chemistry Prevalence of Vertebral Fractures, Vascular Calcifications, and Mortality in Warfarin Treated Hemodialysis Patients
Current Vascular Pharmacology Vitamin D and Stroke: Promise for Prevention and Better Outcome
Current Vascular Pharmacology Left-Right Asymmetry in Embryonic Development and Breast Cancer: Common Molecular Determinants?
Current Medicinal Chemistry Vitamin D, Sunlight, and the Epidemiology of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry The Therapeutic Potential of the Wnt Signaling Pathway in Bone Disorders
Current Molecular Pharmacology Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine